Loading…
Ultralife Corporation is projected to rise to $7.32 by 2027, a +25% move from its current price of $5.85. ULBI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.73 | $5.85 | $5.98 | +0.06% |
| Jul 14 | $5.68 | $5.86 | $6.04 | +0.12% |
| Jul 15 | $5.65 | $5.86 | $6.08 | +0.18% |
| Jul 16 | $5.62 | $5.86 | $6.12 | +0.24% |
| Jul 17 | $5.59 | $5.87 | $6.16 | +0.29% |
| Jul 18 | $5.57 | $5.87 | $6.19 | +0.35% |
| Jul 19 | $5.55 | $5.87 | $6.22 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.55 | $5.87 | $6.22 | +0.41% |
| Week 2 | $5.44 | $5.90 | $6.39 | +0.83% |
| Week 3 | $5.37 | $5.92 | $6.53 | +1.24% |
| Week 4 | $5.31 | $5.95 | $6.66 | +1.66% |
| Week 5 | $5.26 | $5.97 | $6.78 | +2.08% |
| Week 6 | $5.22 | $6.00 | $6.89 | +2.50% |
| Week 7 | $5.18 | $6.02 | $7.00 | +2.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ultralife Corporation designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
The Communications Systems segment provides communications systems and accessories to support military communications systems, such as radio frequency amplifiers, power supplies and cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, and integrated communication systems for fixed or vehicle applications comprising vehicle amplifier-adaptors, vehicle installed power enhanced rifleman appliqué systems, and SATCOM systems. The company sells its products under the Ultralife, Ultralife HiRate, Ultralife Thin Cell, Lithium Power, McDowell Research, AMTI, ABLE, ACCUTRONICS, ACCUPRO, ENTELLION, SWE Southwest Electronic Energy Group, SWE SEASAFE, Excell Battery Group, Criterion Gauge, and POW-R BMS brands through original equipment manufacturers, and industrial and defense supply distributors. In addition, it sells its 9-volt battery to the broader consumer market through national and regional retail chains and online retailers.
It serves government, defense, and commercial sectors. The company was incorporated in 1990 and is headquartered in Newark, New York.
Ultralife Corporation (ULBI) is a player in the Industrials sector, with a current price of $5.83 and a market capitalization of $97.11M. It holds a rank of 4219 among listed securities. The stock’s price outlook is reflected in a year-by-year forecast that begins with a neutral start in 2026 and shifts to bullish momentum through 2030 and beyond, with substantial upside potential by 2040 and 2050.
The forecast shows a progression from a 2026 average of $5.83 to higher annual averages and max values over the coming years, accompanied by rising ROI figures.
A major floor 22.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
The nearest ceiling, 32.6% above — a clean break opens room to run.
A major ceiling 44.0% above — clearing it would confirm fresh momentum.
Key ULBI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ULBI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.92 | Sell | $5.91 | Sell |
| MA 10 | $6.05 | Sell | $6.02 | Sell |
| MA 20 | $6.21 | Sell | $6.19 | Sell |
| MA 50 | $6.46 | Sell | $6.41 | Sell |
| MA 100 | $6.50 | Sell | $6.47 | Sell |
| MA 200 | $6.38 | Sell | $6.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.31 | Neutral |
| Stoch RSI (14) | 14.03 | Buy |
| CCI (20) | -131.46 | Sell |
| Williams %R (14) | -92.16 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -5.03 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 7.84 | Buy |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | -0.59 | Sell |
| Ultimate (7,14,28) | 15.91 | Buy |
| Momentum (10) | -0.38 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 5.76 | Buy |
| ADX (14) | 18.36 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is mixed but leaning neutral. RSI14 stands at 40, signaling room before overbought conditions. The near-term trend shows the stock trading around a support level of $5.83, with a resistance around $7.76.
Moving averages place the mid-range trend slightly above the current price: SMA50 at $6.51 and SMA200 at $6.39. The 30-day trading range spans from $5.02 up to $6.78, illustrating a relatively tight price corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.25 | $5.85 | $7.80 | 0% | Neutral | |
| $5.94 | $7.32 | $9.46 | +25% | Bullish | |
| $5.99 | $7.54 | $10.05 | +29% | Bullish | |
| $6.43 | $8.23 | $11.23 | +41% | Bullish | |
| $6.94 | $9.02 | $12.56 | +54% | Bullish | |
| $6.77 | $8.93 | $12.64 | +53% | Bullish | |
| $8.11 | $10.84 | $15.59 | +85% | Bullish | |
| $9.64 | $13.05 | $19.04 | +123% | Bullish | |
| $9.79 | $13.39 | $19.80 | +129% | Bullish | |
| $10.49 | $14.51 | $21.72 | +148% | Bullish | |
| $14.68 | $21.34 | $33.63 | +265% | Bullish | |
| $23.80 | $37.59 | $63.93 | +542% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.25 | $5.85 | $6.90 | +0.00% |
| August 2026 | $5.06 | $5.94 | $7.13 | +1.54% |
| September 2026 | $5.23 | $6.17 | $7.48 | +3.92% |
| October 2026 | $5.23 | $6.20 | $7.57 | +0.52% |
| November 2026 | $5.18 | $6.17 | $7.57 | -0.63% |
| December 2026 | $5.29 | $6.31 | $7.80 | +2.42% |
Click any year to see its month-by-month ULBI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ULBI is projected to trade between $5.25 and $7.80, averaging $5.85 — a potential gain of 0% from today's $5.85. A consolidation phase looks the most probable path here.
Ultralife Corporation's 2027 outlook centres on $7.32, within a $5.94 to $9.46 range. That is up +25% on the projected 2026 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2028, ULBI could reach as high as $10.05, with a base case around $7.54 and support toward $5.99 — roughly +29% from $5.85. Buyers look set to stay in control over this stretch.
Expect ULBI to range from $6.43 to $11.23 through 2029. The $8.23 average target implies a +41% move from current prices. That is up +9% on the projected 2028 average. Momentum favours further upside here.
The ULBI price prediction for 2030 points to an average of $9.02 (low $6.94, high $12.56) — a potential gain of +54% on today's $5.85. Buyers look set to stay in control over this stretch.
In 2031, ULBI is projected to trade between $6.77 and $12.64, averaging $8.93 — a potential gain of +53% from today's $5.85. That is -1% versus the projected 2030 average. Momentum favours further upside here.
Ultralife Corporation's 2032 outlook centres on $10.84, within a $8.11 to $15.59 range. That is up +21% on the projected 2031 average. That marks a +85% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ULBI could reach as high as $19.04, with a base case around $13.05 and support toward $9.64 — roughly +123% from $5.85. Momentum favours further upside here.
Expect ULBI to range from $9.79 to $19.80 through 2034. The $13.39 average target implies a +129% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ULBI price prediction for 2035 points to an average of $14.51 (low $10.49, high $21.72) — a potential gain of +148% on today's $5.85. Momentum favours further upside here.
In 2040, ULBI is projected to trade between $14.68 and $33.63, averaging $21.34 — a potential gain of +265% from today's $5.85. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ultralife Corporation's 2050 outlook centres on $37.59, within a $23.80 to $63.93 range. That is up +76% on the projected 2040 average. That marks a +542% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ULBI today (≈ 170.940171 ULBI) could be worth
$6,424.83
+$5,424.83 (+542%) by 2050 · US Dollar
Based on the average projected ULBI price of $37.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ULBIwould be worth at today's price.
$1,000 invested in ULBI on Jul 10, 2025 (≈ 113.507373 ULBI) would be worth
$664.02
-$335.98 (-33.6%) today · 0.66× · US Dollar
Based on a ULBI entry price of $8.81 vs. today's $5.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.12 | $955.88 | -4.4% |
| 1 month ago | $6.48 | $902.78 | -9.7% |
| 3 months ago | $6.8 | $860.29 | -14.0% |
| 6 months ago | $6.26 | $934.5 | -6.5% |
| 1 year ago | $8.81 | $664.02 | -33.6% |
| All time (5.0y) ago | $8.43 | $693.95 | -30.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ULBI forecast.
Our base-case forecast reaches $12.00 around 2033.
Implied market cap at $12.00: $199.88M
The multi-year forecast shows a clear bullish trajectory after 2026. The 2026 forecast lists a min of $5.25, an avg of $5.83, and a max of $7.84 with an ROI of 0% and neutral sentiment. By 2027, the avg climbs to $7.31 with a max of $9.52 and ROI of 25.4%, and by 2028 the avg is $7.55 with a max of $10.15 and ROI of 29.6%.
The 2029 forecast shows an avg of $8.27, max $11.39, and ROI of 41.9%, rising further to a 2030 avg of $9.04, max $12.70, and ROI of 55%. The outlook continues with 2031 avg $8.94 (ROI 53.4%), 2032 avg $10.97 (ROI 88.2%), 2033 avg $13.21 (ROI 126.5%), 2034 avg $13.52 (ROI 132%), and 2035 avg $14.70 (ROI 152.2%), all with bullish sentiment. In 2040 the avg is $21.71 (ROI 272.3%), and by 2050 the avg reaches $38.24 (ROI 555.9%), with the highest forecast values indicating strong upside potential.
These figures reflect bullish sentiment across the longer horizon, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast lists 2030 avg $9.04, min $6.89, max $12.70; ROI 55%; sentiment bullish.
The forecast shows bullish sentiment from 2027 onward, with rising averages toward 2030 and beyond, including 2030 avg $9.04 and 2050 avg $38.24 with ROI up to 555.9%; these are estimates, not guarantees.
2033 max is $19.52 and 2040 max is $34.77, so reaching $20 could be met by 2040 on the max path.
Current price is $5.83 and market cap is $97.11M.
RSI14 is 40 with sentiment Neutral. SMA50 is $6.51 and SMA200 is $6.39; support is $5.83 and resistance is $7.76; the 30-day range is $5.02 to $6.78.
Ultralife Corporation Community Discussion
0Share your Ultralife Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.